tiprankstipranks
Trending News
More News >
Renascience Inc. (JP:4889)
:4889
Japanese Market
Advertisement

Renascience Inc. (4889) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4889

Renascience Inc.

(4889)

Rating:51Neutral
Price Target:
Renascience Inc. has a strong financial foundation with low leverage but struggles with profitability and cash flow, affecting its financial performance score. Technical indicators point to a bearish trend, and the high P/E ratio raises valuation concerns. The combination of these factors results in a moderately low overall stock score.

Renascience Inc. (4889) vs. iShares MSCI Japan ETF (EWJ)

Renascience Inc. Business Overview & Revenue Model

Company DescriptionRenascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyRenascience Inc. generates revenue primarily through the sale of its proprietary regenerative medicine products and technologies. The company's key revenue streams include direct sales to healthcare providers, licensing agreements with pharmaceutical companies, and strategic partnerships with research institutions. Additionally, Renascience Inc. may receive funding from government grants and private investors to support its research and development activities. The company leverages its advanced scientific capabilities and expertise to maintain a competitive edge in the biotechnology sector, driving sustainable growth and profitability.

Renascience Inc. Financial Statement Overview

Summary
Renascience Inc. demonstrates financial stability through a strong equity base and low leverage, mitigating risk. However, the company faces challenges in achieving profitability and generating positive cash flows, raising concerns about its operational efficiency and long-term sustainability. Strategic improvements in revenue growth and cost management are essential for enhancing financial performance.
Income Statement
45
Neutral
Renascience Inc. shows a significant negative EBIT and EBITDA, indicating high operational losses over the recent periods. Despite a net income improvement in the TTM period, the company's revenue growth has been inconsistent, with fluctuations over the past few years. The gross profit margin remains strong, suggesting effective cost management in production but failing to translate into overall profitability.
Balance Sheet
75
Positive
The company maintains a robust equity position with a high equity ratio, indicating financial stability and low leverage, as evidenced by zero total debt in the TTM period. This suggests a conservative financial structure, minimizing risk exposure. However, the return on equity is poor due to consistent net losses, which impacts investor returns negatively.
Cash Flow
50
Neutral
Renascience Inc. exhibits weak cash flow performance, with negative operating and free cash flows in multiple periods, reflecting challenges in generating cash from operations. The lack of recent capital expenditures may suggest underinvestment, potentially affecting future growth. The cash flow to net income ratios are not assessable due to zero or negative values, highlighting liquidity concerns.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue131.94M132.69M194.16M100.55M139.33M209.80M
Gross Profit127.90M128.95M165.64M100.30M80.97M179.82M
EBITDA125.21M143.82M-250.50M-332.49M-244.65M-89.39M
Net Income113.33M113.43M-258.33M-335.80M-254.29M-100.05M
Balance Sheet
Total Assets1.87B1.87B2.09B2.27B2.44B1.07B
Cash, Cash Equivalents and Short-Term Investments1.80B1.80B2.03B2.21B2.39B1.03B
Total Debt0.000.00356.10M309.60M199.23M475.65M
Total Liabilities151.21M151.21M482.11M409.76M237.17M505.10M
Stockholders Equity1.72B1.72B1.61B1.87B2.20B561.53M
Cash Flow
Free Cash Flow0.00-177.14M-232.10M-286.87M-231.66M-90.27M
Operating Cash Flow0.00-176.34M-230.52M-284.64M-230.49M-89.25M
Investing Cash Flow0.00382.15M-1.57M232.00K-296.00K-1.72M
Financing Cash Flow0.00-52.18M46.50M110.37M1.59B135.65M

Renascience Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1999.00
Price Trends
50DMA
2537.88
Negative
100DMA
2021.57
Negative
200DMA
1417.87
Positive
Market Momentum
MACD
-178.66
Positive
RSI
31.38
Neutral
STOCH
17.46
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4889, the sentiment is Negative. The current price of 1999 is below the 20-day moving average (MA) of 2425.30, below the 50-day MA of 2537.88, and above the 200-day MA of 1417.87, indicating a neutral trend. The MACD of -178.66 indicates Positive momentum. The RSI at 31.38 is Neutral, neither overbought nor oversold. The STOCH value of 17.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4889.

Renascience Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
¥9.67B38.52
4.58%-39.30%
58
Neutral
¥20.39B
6.33%-250.29%
52
Neutral
¥17.47B
-22.81%2.69%
51
Neutral
$7.95B-0.40-42.50%2.21%22.29%-1.85%
51
Neutral
¥25.41B400.19
-27.00%
49
Neutral
¥18.57B206.40
13.83%34.66%
47
Neutral
¥19.45B
8.47%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4889
Renascience Inc.
1,999.00
1,634.00
447.67%
JP:4599
StemRIM Inc.
313.00
-100.00
-24.21%
JP:4978
ReproCELL Inc.
196.00
67.00
51.94%
JP:7096
StemCell Institute
944.00
-647.57
-40.69%
JP:7774
Japan Tissue Engineering Co., Ltd.
502.00
-25.00
-4.74%
JP:7776
CellSeed Inc.
504.00
-383.00
-43.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 02, 2025